0000898770-22-000002.txt : 20220126 0000898770-22-000002.hdr.sgml : 20220126 20220126065340 ACCESSION NUMBER: 0000898770-22-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220126 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220126 DATE AS OF CHANGE: 20220126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHARPS COMPLIANCE CORP CENTRAL INDEX KEY: 0000898770 STANDARD INDUSTRIAL CLASSIFICATION: HAZARDOUS WASTE MANAGEMENT [4955] IRS NUMBER: 742657168 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34269 FILM NUMBER: 22555651 BUSINESS ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 713-432-0300 MAIL ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: US MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19970128 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL POLYMERS TECHNOLOGIES INC DATE OF NAME CHANGE: 19930916 8-K 1 smed-20220126.htm 8-K smed-20220126
0000898770FALSE00008987702021-12-312022-01-26

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
January 26, 2022
SHARPS COMPLIANCE CORP.
Commission File No. 001-34269

(Exact Name Of Registrant As Specified In Its Charter)
 Delaware74-2657168

(State Or Other Jurisdiction Of
Incorporation Or Organization)

(IRS Employer
Identification No.)
9220 Kirby Drive, Suite 500
Houston, Texas 77054
(Address Of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code)
713-432-0300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Shares, $0.01 Par ValueSMEDThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is a an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




TABLE OF CONTENTS
Item 2.02    Disclosure of Results of Operations and Financial Condition

Item 9.01    Financial Statements and Exhibits

        SIGNATURES

        INDEX TO EXHIBITS

        Press Release



















































Item 2.02. Results of Operations and Financial Condition.
On January 26, 2022, Sharps Compliance Corp. (the "Company") announced its results of operations for the three and six months ended December 31, 2021. A copy of the earnings release is attached as Exhibit 99.1.
The information in this Current Report is being furnished pursuant to Item 2.02 including Exhibit 99.1 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), and Section 11 of the Securities Act of 1933, as amended, otherwise subject to the liabilities of those sections nor incorporated by reference in any filing under the Exchange Act unless specifically referenced in such subsequent filing as being incorporated by reference. The Company does not undertake a duty to update the information in this Current Report and cautions that the information included in this Current Report is current only as of January 26, 2022 and may change thereafter.


Item 9.01. Financial Statements and Exhibits.
(a)Financial Information
    Not applicable.
(b) Pro Forma Financial Information
    Not applicable.
(c)Exhibits
Exhibit        Description
99.1
Press Release, dated January 26, 2022.


    





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 26, 2022
SHARPS COMPLIANCE CORP.


By: /s/ DIANA P. DIAZ
Diana P. Diaz
Executive Vice President and Chief Financial Officer






INDEX TO EXHIBITS

Exhibit Number            

EX-99.1 2 ex991-sharpscomplianceq2fy.htm EX-99.1 Document
EXHIBIT 99.1
IMMEDIATE RELEASE

Sharps Compliance Reports Fiscal 2022 Second Quarter Results

Second quarter revenue of $18.9 million increased 11% from the prior year and 36% sequentially
Route-based customer locations increased 17% to 17,400 from 14,900 in the prior year
Professional market billings grew 15% compared to prior year second quarter
Unused medication revenue increased 9% driven by increased Inner Liner sales
Immunization-related mailback billings increased by $2.8 million sequentially as compared to 1Q22, from $1.8 million to $4.6 million, reflecting COVID-19 vaccines and booster shots administered in the Retail Pharmacy market
Closed on Affordable Medical Waste acquisition on October 22, 2021
Partnership with PharMerica recently announced to address the cost-effective and compliant management of unused medications in the long-term care market
Cash balance of $36.0 million at December 31, 2021

HOUSTON, Texas, January 26, 2022 - Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today reported financial results for the second quarter of fiscal 2022, ended December 31, 2021.

Revenue in the second quarter of fiscal 2022 grew 11% to $18.9 million, compared to $17.0 million in the same prior year quarter and grew 36% sequentially. Customer billings of $17.0 million decreased 8% compared to $18.5 million for the same prior year quarter. Second quarter 2022 gross margin increased to 35%, as compared to gross margin of 33% in the second quarter of 2021. SG&A increased by approximately $0.6 million or 17% to $4.4 million in the second quarter of fiscal 2022, compared to the same prior year quarter. The increase in SG&A is related primarily to $0.2 million in acquisition related costs, a $0.2 million increase in the accrual of management incentive compensation and continued investment in sales and marketing.

The Company reported operating income of $2.0 million in the second quarter of 2022, compared to operating income of $1.7 million in the second quarter of 2021. Sharps recorded net income of $1.4 million, or $0.07 per basic and diluted share, in the second quarter of fiscal 2022, as compared to net income of $1.2 million, or $0.07 per basic and diluted share in the second quarter of fiscal 2021. Sharps recorded improved EBITDA of $2.6 million in the second quarter of fiscal 2022 compared to EBITDA of $2.2 million in the second quarter of fiscal 2021. (See Reconciliation of Net Income to EBITDA in the supplemental table included at the end of this release).

David P. Tusa, President and Chief Executive Officer of Sharps, stated, “We delivered strong second quarter results as demonstrated by solid revenue growth, improved gross margin and consistent profitability, which we believe is reflective of our success in establishing Sharps as a leading and comprehensive provider of medical, pharmaceutical and hazardous waste management solutions. We were pleased with the 17% increase in the route-based customer locations which was directly related to continued demand for our solution offerings across the markets we serve, and particularly our Professional market billings which increased 15% for the second quarter. Unused medication billings increased 9% for the quarter as a result of a 25% increase in the number of MedSafe


Inner Liners sold for the quarter. The sequential $2.8 million increase in quarterly immunization-related customer billings was a result of retail pharmacies continuing to administer COVID-19 vaccines and booster shots. For the second quarter and fiscal year to date, the reduction in customer billings for the Long-Term Care segment was a result of significantly increased volume, in the prior year, driven by the impact of COVID-19 in Long-Term Care communities.”

Tusa added, “We pride ourselves on our ability to solve complex problems for our customers. The latest problem we are solving is the industry challenge regarding the proper, cost-effective, and compliant management of unused medications, including controlled substances and hazardous wastes, such as blood thinners, in the long-term care and assisted living markets. In fact, the Secure and Responsible Drug Disposal Act approved by the DEA in 2014 was written primarily to address proper and compliant unused medication management practices in long-term care communities which have been very inconsistent. To help customers meet the new requirements set forth in the new DEA rules, we designed the MedSafe to address the proper and cost-effective collection and destruction of unused medications, including controlled substances. MedSafe has seen solid demand from retail pharmacy and other settings, such as government, and we believe Sharps is the leader in the retail pharmacy and government markets for the cost-effective and compliant disposal of unused medications. We are now taking our vast knowledge, experience and success gained from introducing MedSafe in the retail pharmacy and government settings and bringing this solution to the long-term care and assisted living markets, where we believe the MedSafe has the opportunity to become the industry standard. We are excited about our recently announced partnership with PharMerica, a nationwide leader in long-term care pharmacy services, and look forward to working with them to solve a complex problem.”

Second Quarter Review

Professional market billings increased 15% to $5.2 million in the second quarter of fiscal 2022 as compared to $4.5 million in the second quarter of 2021 consistent with the increase in route-based customer locations.

Retail market billings grew 4% to $6.4 million in the second quarter of fiscal 2022 as compared to $6.1 million in the same prior year period. Within the retail market, immunization related orders were down slightly at $4.6 million in the second quarter of fiscal 2022 compared to $4.8 million in the prior year.

Pharmaceutical Manufacturer market billings decreased by $1.2 million to $1.9 million in the second quarter of fiscal 2022 as compared to $3.1 million in the same prior year period due to the timing of inventory builds for patient support programs, driving over half of the $1.7 million decrease in mailback solution billings.

Long-Term Care billings decreased by $0.3 million to $0.8 million in the second quarter of fiscal 2022 compared to $1.1 million in the prior year period, related primarily to heightened volumes of COVID-19 related waste management in the prior year, most of which adversely impacted the route-based business customer billings.

Home Health Care market billings decreased $0.8 million to $2.0 million in the second quarter of fiscal 2022 compared to $2.8 million in the second quarter of fiscal 2021 due to the timing of distributor orders, driving some of the $1.7 million decrease in mailback solution billings.

Billings for Unused Medications grew 9% to $1.9 million in the second quarter of fiscal 2022 as compared to $1.7 million in the same prior year period as result of the 25% increase in the number of MedSafe Inner Liners sold.




First Six Months Fiscal 2022 Results

Sharps recorded revenue of $32.8 million in the first half of fiscal 2022, an increase of 9% compared to revenue of $30.2 million in the first half of fiscal 2021. Customer billings decreased 7% to $29.7 million for the first half of fiscal 2022. Professional market billings increased 12% to $9.7 million in the first half of fiscal 2022 as compared to $8.7 million in the same prior year period. Retail market billings increased 5% to $10.2 million as compared to $9.8 million in the first half of fiscal 2021, with billings for flu shot / COVID-19 related orders relatively flat at $6.4 million, and unused medications billings also relatively flat at $2.2 million. Long-Term Care market billings decreased 35% to $1.5 million as compared to $2.4 million in the prior year period. During the first half of fiscal 2022, Pharmaceutical Manufacturer market billings decreased 44% to $2.4 million as compared to $4.2 million in the first half of fiscal 2021. Home Health Care market billings decreased 23% to $4.0 million for the first half of fiscal 2022 compared to $5.2 million in the first half of 2021.

Gross margin was essentially flat at 30.6% for the first half of fiscal 2022 as compared to 30.7% in first half of fiscal 2021 despite being negatively impacted by a $0.8 million increase in the fixed cost component of cost of sales. SG&A expense increased 14% to $8.6 million in the first half of fiscal 2022 compared to $7.5 million in the first half of fiscal 2021, related to $0.2 million in acquisition related costs, a $0.5 million increase in the accrual of management incentive compensation and the Company’s continued investments in sales and marketing. The Company recorded operating income of $1.0 million in the first half of fiscal 2022 as compared to operating income of $1.3 million in the first half of fiscal 2021.

Net income for the first half of fiscal 2022 was $0.6 million, or $0.03 per basic and diluted share compared to net income of $0.9 million or $0.06 per basic and diluted share for the first half of fiscal 2021.

Sharps recorded EBITDA of $2.2 million in the first half of fiscal 2022, consistent with EBITDA in the first half of fiscal 2021. (See Reconciliation of Net Income to EBITDA in the supplemental table included at the end of this release).

Financial Flexibility and a Strong Balance Sheet

Cash was $36.0 million at December 31, 2021, compared to cash of $27.8 million at June 30, 2021. The Company had working capital of $42.8 million at December 31, 2021 compared to working capital of $27.9 million at June 30, 2021.

Mr. Tusa concluded, “Looking forward, we’re energized to continue capitalizing on the opportunities we’re seeing to grow our leadership position in all of the markets we serve and all solutions we offer. We continue to focus on the growth of our route-based business and complementing this with acquisition opportunities. The acquisition pipeline remains vibrant, and we believe we have the opportunity to close more acquisitions during the calendar year 2022.

“Regarding immunizations, we’ve seen that the ongoing emergence of new variants causes the COVID-19 related business landscape to remain fluid. As we move through the balance of fiscal year 2022, future immunization-related orders should be driven by the timing and volume of the continued roll out of COVID-19 shots and boosters. As a point of reference, only approximately 40% of fully vaccinated Americans have received a booster to-date. Additionally, there are new vaccines being developed to address specific variants, such as Omicron, which could be available by March of 2022. We remain confident that we are well positioned to continue to support our immunization customers, with mailback inventory and increased treatment capacity to meet the continuing demands of this business."






Second Quarter Fiscal Year 2022 Webcast and Conference Call

The Company will host a teleconference today beginning at 11:00 a.m. Eastern Time, during which management will review the financial and operating results for the period and discuss Sharps’ corporate strategy and outlook. A question-and-answer session will follow.

The Sharps Compliance conference call can be accessed by domestic callers by dialing (888) 506-0062. International callers may access the call by dialing (973) 528-0011. Callers should use conference entry code 618730. The webcast can be monitored at www.sharpsinc.com.

A telephonic replay will be available through February 25, 2022. To listen to the replay, domestic callers should dial (877) 481-4010 and international callers should dial (919) 882-2331 and enter replay ID number 44124. Transcript will also be posted to the Sharps Compliance website, once available.

About Sharps Compliance Corp.

Headquartered in Houston, Texas, Sharps Compliance (NASDAQ: SMED) is a leading business-to-business services provider to the healthcare, long-term care and retail pharmacy markets. Sharps Compliance offers comprehensive solutions for the management of regulated medical waste, hazardous waste and unused medications. For more information, visit: www.sharpsinc.com.

Forward-Looking Statements

The information made available in this news release contains certain forward-looking statements relating to the Company that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this document, the words "may," “position,” "plan," “potential,” “designed,” “continue,” "anticipate," "believe," "expect," "estimate," “project,” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements. Such statements reflect the known and unknown risks, uncertainties and assumptions related to certain factors including, without limitation, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein including the impact of the coronavirus COVID-19 (“COVID-19”) pandemic on our operations and financial results. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. Consequently, no forward-looking statements can be guaranteed. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the Company’s Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K, and our other filings with the Securities and Exchange Commission. Actual results may vary materially. You are cautioned not to place undue reliance on any forward-looking statements. You should also understand that it is not possible to predict or identify all such factors and as such should not consider the preceding list or the risk factors to be a complete list of all potential risks and uncertainties. The Company does not intend to update these forward-looking statements.





Non-GAAP Measures

This release contains certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”), including customer billings information and EBITDA. The Company believes this information is useful to investors and other interested parties. EBITDA is a significant performance metric used by management and by external users of our financial statements such as investors, research analysts and others to assess the financial performance of our assets without regard to financing methods, capital structure or historical cost basis; the ability of our assets to generate cash sufficient to pay interest costs and support our indebtedness; and our operating performance and return on capital as compared to those of other companies in our industry. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities or measure of our liquidity and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.

For more information contact:
Diana P. Diaz
Sharps Compliance Corp.
Executive Vice President and Chief Financial Officer
Phone: (713) 660-3547
Email: ddiaz@sharpsinc.com
John Nesbett/Jennifer Belodeau
IMS Investor Relations
Phone: (203) 972-9200
Email: jnesbett@institutionalms.com

FINANCIAL TABLES FOLLOW


















Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)

Three-Months Ended Six-Months Ended
December 31,December 31,
20212020% Change20212020% Change
Revenue$18,878 $17,011 11.0 %$32,793 $30,162 8.7 %
Cost of revenue12,271 11,374 7.9 %22,765 20,902 8.9 %
Gross profit6,607 5,637 17.2 %10,028 9,260 8.3 %
Gross margin35.0 %33.1 %30.6 %30.7 %
SG&A expense4,388 3,756 16.8 %8,588 7,544 13.8 %
Depreciation and amortization236 205 454 409 
Operating Income1,983 1,676 986 1,307 
Operating margin10.5 %9.9 %3.0 %4.3 %
Interest income14 — 14 — 
Interest expense(58)(47)(114)(79)
Income associated with derivative instrument27 10 34 15 
Total other expense(17)(37)(66)(64)
Income before income taxes1,966 1,639 920 1,243 
Income tax expense529 411 273 308 
Net Income$1,437 $1,228 $647 $935 
Net Income Per Share
Basic and Diluted$0.07 $0.07 $0.03 $0.06 
Weighted Average Shares Outstanding
Basic19,245 16,497 18,562 16,444 
Diluted19,400 16,929 18,656 16,875 


Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31,June 30,
20212021
ASSETS:
Current assets:
Cash$36,001 $27,767 
Accounts receivable, net13,047 9,738 
Inventory6,821 6,114 
Contract asset18 20 
Prepaid and other current assets1,857 1,459 
Total current assets57,744 45,098 
Property, plant and equipment, net11,155 10,843 
Operating lease right of use asset9,073 8,353 
Financing lease right of use asset, net980 907 
Inventory, net of current portion957 989 
Other assets154 110 
Goodwill7,996 6,735 
Intangible assets, net2,772 2,239 
Deferred tax asset, net— 157 
Total assets$90,831 $75,431 
Current liabilities
Accounts payable$3,592 $2,922 
Accrued liabilities3,208 3,940 
Operating lease liability2,457 2,368 
Financing lease liability189 160 
Current maturities of long-term debt480 735 
Contract liability5,062 7,028 
Total current liabilities14,988 17,153 
Contract liability, net of current portion408 1,461 
Operating lease liability, net of current portion6,752 6,118 
Financing lease liability, net of current portion804 741 
Other liabilities23 45 
Deferred tax liability, net53 — 
Long-term debt, net of current portion3,172 3,329 
Total liabilities26,200 28,847 
Stockholders' equity64,631 46,584 
Total liabilities and stockholders' equity$90,831 $75,431 


Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing and Revenue Information
(in thousands)
(Unaudited)

Three-Months Ended December 31,
2021% Total2020$ Change%
BILLINGS BY MARKET:
Retail$6,365 37.5 %$6,139 $226 3.7 %
Professional5,199 30.6 %4,538 661 14.6 %
Home Health Care2,028 11.9 %2,832 (804)(28.4)%
Pharmaceutical Manufacturer1,901 11.2 %3,062 (1,161)(37.9)%
Long-Term Care752 4.4 %1,060 (308)(29.1)%
Government564 3.3 %497 67 13.5 %
Environmental54 0.3 %179 (125)(69.8)%
Other137 0.8 %159 (22)(13.8)%
Subtotal17,000 100.0 %18,466 (1,466)(7.9)%
GAAP Adjustment *1,878 (1,455)3,333 
Revenue Reported$18,878 $17,011 $1,867 11.0 %
Six-Months Ended December 31,
2021% Total2020$ Change%
BILLINGS BY MARKET:
Retail$10,232 34.4 %$9,786 $446 4.6 %
Professional9,716 32.7 %8,671 1,045 12.1 %
Home Health Care3,967 13.3 %5,180 (1,213)(23.4)%
Pharmaceutical Manufacturer2,397 8.1 %4,241 (1,844)(43.5)%
Long-Term Care1,530 5.1 %2,369 (839)(35.4)%
Government1,271 4.3 %1,012 259 25.6 %
Environmental85 0.3 %314 (229)(72.9)%
Other526 1.8 %321 205 63.9 %
Subtotal29,724 100.0 %31,894 (2,170)(6.8)%
GAAP Adjustment *3,069 (1,732)4,801 
Revenue Reported$32,793 $30,162 $2,631 8.7 %
*Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue. Customer billings include all invoiced amounts for products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales, (ii) recognition of certain revenue associated with product returned for treatment and destruction and (iii) provisions for certain product returns and discounts to customers which are accounted for as reductions in sales in the same period the related sales are recorded.


Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing by Solution Information
(in thousands)
(Unaudited)

Three-Months Ended December 31,
2021% Total2020$ Change%
BILLINGS BY SOLUTION:
Mailbacks$10,192 60.0 %$11,907 $(1,715)(14.4)%
Route-Based Pickup3,551 20.9 %3,491 60 1.7 %
Unused Medications1,865 11.0 %1,713 152 8.9 %
Third Party Treatment54 0.3 %179 (125)(69.8)%
Other1,338 7.8 %1,176 162 13.8 %
Total Billings by Solution$17,000 100.0 %$18,466 $(1,466)(7.9)%
Six-Months Ended December 31,
2021% Total2020$ Change%
BILLINGS BY SOLUTION:
Mailbacks$15,749 53.0 %$18,346 $(2,597)(14.2)%
Route-Based Pickup6,750 22.7 %6,647 103 1.5 %
Unused Medications4,494 15.1 %4,074 420 10.3 %
Third Party Treatment85 0.3 %314 (229)(72.9)%
Other2,646 8.9 %2,513 133 5.3 %
Total Billings by Solution$29,724 100.0 %$31,894 $(2,170)(6.8)%





























Sharps Compliance Corp. and Subsidiaries
Supplemental Table to Reconcile Net Income to EBITDA*
(in thousands)
(Unaudited)

Three-Months Ended Six-Months Ended
December 31,December 31,
2021202020212020
Net Income$1,437 $1,228 $647 $935 
Income tax expense529 411 273 308 
Interest expense, net44 47 100 79 
Depreciation and amortization584 500 1,166 923 
EBITDA$2,594 $2,186 $2,186 $2,245 
*The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income, plus income tax expense (benefit), net interest expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity’s financial results, and accordingly, EBITDA should not be considered an alternative to operating income, net income, or cash flows as determined under generally accepted accounting principles and as reported by the Company.



EX-101.SCH 3 smed-20220126.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 smed-20220126_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 smed-20220126_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
1 Months Ended
Jan. 26, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 26, 2022
Entity Registrant Name SHARPS COMPLIANCE CORP
Entity File Number 001-34269
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 74-2657168
Entity Address, Address Line One 9220 Kirby Drive
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77054
City Area Code 713
Local Phone Number 432-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, $0.01 Par Value
Trading Symbol SMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000898770
Amendment Flag false
XML 7 smed-20220126_htm.xml IDEA: XBRL DOCUMENT 0000898770 2021-12-31 2022-01-26 0000898770 false 8-K 2022-01-26 SHARPS COMPLIANCE CORP 001-34269 DE 74-2657168 9220 Kirby Drive Suite 500 Houston TX 77054 713 432-0300 false false false false Common Shares, $0.01 Par Value SMED NASDAQ false 2022-01-26 2022-01-26 2022-01-26 2022-01-26 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://sharpsinc.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports smed-20220126.htm ex991-sharpscomplianceq2fy.htm smed-20220126.xsd smed-20220126_lab.xml smed-20220126_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "smed-20220126.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "smed-20220126.htm" ] }, "labelLink": { "local": [ "smed-20220126_lab.xml" ] }, "presentationLink": { "local": [ "smed-20220126_pre.xml" ] }, "schema": { "local": [ "smed-20220126.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "smed", "nsuri": "http://sharpsinc.com/20220126", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "smed-20220126.htm", "contextRef": "ifb15684b4bde415d9bba0f022f381154_D20211231-20220126", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://sharpsinc.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "smed-20220126.htm", "contextRef": "ifb15684b4bde415d9bba0f022f381154_D20211231-20220126", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000898770-22-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000898770-22-000002-xbrl.zip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end